Loading clinical trials...

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19 | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19: a Randomized, Double-blind, Parallel-controlled Study

NCT05719012•Shanghai East Hospital

View on ClinicalTrials.gov

Summary

To explore the efficacy and safety of Umbilical cord mesenchymal stem cells in the treatment of long COVID-19

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The age ranges from 18 to 85 (inclusive), regardless of gender.
•2. Patients with Confirmed SARS-CoV-2 infection, according to the consensus of the Chinese diagnostic criteria for COVID-19 (Tentative tenth Edition).
•3. Patients with symptoms of long COVID-19 3 months from the onset of COVID-19, lasting for at least 2 months, and the symptoms cannot be explained by other diseases.
•4. Be expected to live longer than 1 year.
•5. Volunteer to participate in this clinical study and sign the written informed consent.

Exclusion Criteria

•1. Those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation.
•2. T lymphocyte abnormality, HIV positive.
•3. Highly allergic or have a history of severe allergy.
•4. Pregnant and lactating women.
•5. Patients with severe autoimmune disease history;
•6. Patients with uncontrolled chronic diseases or serious complications;
•7. Patients with malignant tumors;
•8. Patients with pulmonary embolism, acute coronary syndrome, cerebral embolism or at high risk of thromboembolism;
•9. Patients with severe organ dysfunction
•10. Other situations that the researchers think are not suitable for participating in this study

Locations (1)

Shanghai East Hosptial

Shanghai, China

Key Dates

Start Date

April 1, 2023

Primary Completion Date

December 1, 2023

Completion Date

March 30, 2024

Last Updated

November 21, 2023

Conditions

Long COVID-19

Interventions

UC-MSCs

BIOLOGICAL

LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19

NCT05379556

Long Covid-19

View study

RECRUITINGPHASE3

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

NCT06960928

Long COVID-19

View study

ACTIVE_NOT_RECRUITINGPHASE2

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 21, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19

Inclusion Criteria

Exclusion Criteria

LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Synbiotic Therapy for NP-PASC

Evaluating the Impact of a Functional and Cognitive Strategy in Patients with Long Covid-19

Long Term Impact of COVID-19